ASN's Mission

ASN leads the fight to prevent, treat, and cure kidney diseases throughout the world by educating health professionals and scientists, advancing research and innovation, communicating new knowledge, and advocating for the highest quality care for patients.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on Twitter

Kidney Week

Abstract: SA-PO364

CD80 and CD163 as Biomarkers of Nephrotic Syndrome

Session Information

Category: Glomerular Diseases

  • 1202 Glomerular Diseases: Immunology and Inflammation

Authors

  • Hogan, Marie C., Mayo Clinic, Rochester, Minnesota, United States
  • Gonzalez guerrico, Anatilde M., Mayo Clinic, Rochester, Minnesota, United States
  • Troost, Jonathan P., University of Michigan, Ann Arbor, Michigan, United States
  • Wright, Adam M., Mayo Clinic, Rochester, Minnesota, United States
  • Fervenza, Fernando C., Mayo Clinic, Rochester, Minnesota, United States
  • Klee, George G., Mayo Clinic, Rochester, Minnesota, United States
  • Lieske, John C., Mayo Clinic, Rochester, Minnesota, United States

Group or Team Name

  • NEPTUNE Consortium
Background

Cellular expression of CD80 and CD163 may play a role in the pathogenesis of certain glomerulopathies. Urinary or blood concentrations may predict and/or track response to specific immunosuppressive therapies and long term renal function.

Methods

Urine was obtained from Mayo Clinic patients (286) and NEPTUNE cohort participants (104) with biopsy-proven minimal change disease (MCD, 103), focal segmental glomerulosclerosis (FSGS, 97), lupus nephritis (LN, 31), IgA nephropathy (IgAN, 28), and membranous nephropathy (MN, 54), as well as non glomerular disease patients with autosomal dominant polycystic kidney disease (ADPKD, 9), pyuria (19), and controls (34). Data expressed as (mean, median (IQR)) was analyzed by Kruskal-Wallis test, generalized estimating equation models (GEE) or receiver operating characteristic (AUC) curve analysis.

Results

CD80/Creatinine and CD163/Creatinine were higher in relapse vs remission in paired urine samples of MCD and FSGS cases (GEE: Active vs. remission p<0.0001); MCD vs. FSGS p<0.0001). Urinary CD80/Creatinine ratios were higher in active MCD, LN, DN and CD163/Creatinine was higher in active LN compared to active cases of other glomerular diseases or controls (Table 1). Differences remained significant after adjusting for proteinuria (p≤0.01; GEE).

Conclusion

Urinary CD80 and CD163 excretions varied between disease groups and by disease activity. These results suggest a pathogenic role for these molecules in certain glomerular diseases, including diabetic nephropathy.

Urinary CD80/creat and CD163/Creat discriminate by proteinuric kidney disease type.
 # samplesCD80 (ng/g Creat)
Median (IQR)
p vs. Controlp vs. MCDCD163 (µg/g Creat
Median (IGR)
p vs. Control
Control3246 (21, 76)REF<0.010.3 (0.2, 0.9)REF
MCD47139 (79, 221)<0.01REF5.3 (2.2, 18.3)<0.01
FSGS5882 (40, 114)0.03<0.015.6 (3.1, 8.6)<0.01
IgAN919 (7, 52)0.09<0.013.9 (2.9, 6.7)<0.01
Lupus10165 (76, 395)0.020.8651.1 (13.4, 156.1)<0.01
MN2764 (28, 96)0.18<0.017.3 (4.7, 11.4)<0.01
DN8160 (124, 300)0.050.5114.1 (13.2, 30.3)<0.01
Pyuria1931 (14, 44)0.20<0.010.4 (0.2, 0.8)0.89
ADPKD945 (34, 61)0.070.020.8 (0.3, 2.4)0.02

GEE analysis of Log-CD80/Creat and CD163/Creat across controls, pyuria, ADPKD and samples with proteinuria ≥2 for DN, FSGS, IgAN, Lupus, MCD, and MN.

Funding

  • Commercial Support